Advertisement

Neue Aspekte der antihypertensiven Therapie bei Diabetes mellitus

  • R. G. Bretzel
Conference paper

Zusammenfassung

Ein letal ausgehendes diabetisches Koma ist heute glücklicherweise eine Seltenheit. Die häufigsten Todesursachen bei Diabetikern sind demgegenüber durch vaskuläre Erkrankungen bedingt. So sterben etwa zwei Drittel aller Diabetiker an koronarer Herzerkrankung, apoplektischem Insult oder generalisierter Arteriosklerose. Ein Befall der renalen Gefäße und der glomerulären Schlingen-kapillaren führt häuflg zu einer diabetischen Nephropathie, die mit etwa 6% in der Todesursachenstatistik bei Diabetikern zu Buche schlägt. Unter den Diabetikern jedoch, die bereits vor ihrem 20. Lebensjahr erkranken, verstirbt jeder 2. Patient letztlich an Nierenversagen [114]. Diabetiker weisen gegenüber altersentsprechenden Nichtdiabetikern ein stark erhöhtes Risiko für eine koronare Herzerkrankung (durchschnittlich 5fach) und für eine Nephropathie (durchschnittlich 15- bis 20fach) auf [146].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Adams S (1929) A study of the blood pressure of pat1ents w1th d1abetes mell1tus. Am J Med Sc1 177: 195–201Google Scholar
  2. 2.
    Amer1can D1abetes Assoc1at1on (1989) Consensus statement: role of card1ovascular r1sk factors 1n prevent1on and treatment of macrovascular d1sease 1n d1abetes. D1abetes Care 12: 573–579Google Scholar
  3. 3.
    Amer1can D1abetes Assoc1at1on (1990) Cl1n1cal Pract1ce Recommendat1ons 1989–1990. Nutr1t1onal recommendat1ons and pr1nc1ples for 1nd1v1duals w1th d1abetes mell1tus. D1abetes Care 13 [suppl. 1]: 18–25Google Scholar
  4. 4.
    Ames RP (1983) Negat1ve effects of d1uret1c drugs on metabol1c r1sk factors for coronary heart d1sease: poss1ble alternat1ve drug therap1es. Am J Card1ol 51: 632–638Google Scholar
  5. 5.
    Ames RP, H1ll P (1976) 1ncrease 1n serum-l1p1ds dur1ng treatment of hypertens1on w1th chlorthal1done. Lancet 1: 721–723Google Scholar
  6. 6.
    Aronoff SL, Schn1der S, Smeltzer J, MacKay W, Tchou P, Rusforth N, Müller M, Bennett PH (1981) Ur1nary excret1on and renal clearance of spec1f1c plasma prote1ns 1n d1abetes of short and long durat1on. D1abetes 30: 656–663Google Scholar
  7. 7.
    Aronson PS (1982) Red-cell sod1um-l1th1um countertransport and essent1al hypertens1on. N Engl J Med 307: 317–321PubMedGoogle Scholar
  8. 8.
    Aurell M, Pettersson M, Berglund GC (1975) Ren1n-ang1otens1on-system 1n essent1al hypertens1on. Lancet 2: 342–343PubMedGoogle Scholar
  9. 9.
    Baba T, Murabayash1 S, Takebe K (1989) Compar1son of the renal effects of ang1otens1n convert1ng enzyme 1nh1b1tor and calc1um antagon1st 1n hypertens1ve type 2 (non-1nsul1n-dependent) d1abet1c pat1ents w1th m1croalbum1nur1a: a random1zed controlled tr1al. D1abetolog1a 32: 40–44Google Scholar
  10. 10.
    Barret-Connor E, Cr1qu1 MH, Klauber MR, Holdbrook M (1981) D1abetes and hypertens1on 1n a commun1ty of older adults. Am J Ep1dem1ol 113: 276–284Google Scholar
  11. 11.
    Baumann R, Thybusch D, Göd1cke W, Kle1nau E, Banv1 D (1971) Funkt1onsk1net1k von 1nsul1n, L1p1den and Cort1sol nach 1.v. Glukosebelastung 1n Frühstad1en der essent1ellen Hyperton1e. Dtsch Gshts W 26: 525–536Google Scholar
  12. 12.
    Beck-N1elsen H, Pedersen O, Sorensen NS (1980) Effects of d1etary changes on cellular 1nsul1n b1nd1ng and 1n v1vo 1nsul1n sens1t1v1ty. Metabol1sm 29: 482–487Google Scholar
  13. 13.
    Bengtsson C (1988) Ant1hypertens1ve therapy and r1sk of d1abetes. 1n: Gr1es FA, We1dman P (eds) D1abetes and hypertens1on. Spr1nger, Berl1n He1delberg New York Tokyo, pp 18–24Google Scholar
  14. 14.
    Bengtsson C, Blohme G, Lap1dus L, L1ndqu1st O, Lundgren H, Nyström E, Petersen K, S1gurdsson JA (1984) Do ant1hypertens1ve drugs prec1p1tate d1abetes? Br Med J 289: 1495–1497Google Scholar
  15. 15.
    Bengtsson C, Blohme G, Lap1dus L, Lundgren H (1988) D1abetes 1n hypertens1ve women: an effect of ant1hypertens1ve drugs or the hypertens1ve state per se? D1abet1c Med 5: 261–264Google Scholar
  16. 16.
    Björck S, Nyberg G, Mulec H, Granerus G, Herl1tz H, Aurell M (1986) Benef1c1al effects of ang1otens1n convert1ng enzyme 1nh1b1t1on on renal funct1on 1n pat1ents w1th d1abet1c nephropathy. Br Med J 293: 471–474Google Scholar
  17. 17.
    Björntorp P (1976) Exerc1se 1n the treatment of obes1ty. Cl1n Endocr1nol Metab 5: 431–439Google Scholar
  18. 18.
    Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of prote1nur1a on relat1ve mortal1ty 1n type 1 (1nsul1n-dependent) d1abetes mell1tus. D1abetolog1a 28: 590–596Google Scholar
  19. 19.
    Breckenr1dge A, Dollery CT, Welborn TA, Fraser R (1967) Glucose tolerance 1n hypertens1ve pat1ents on long-term d1uret1c treatment. Lancet 1: 61–64Google Scholar
  20. 20.
    Bretzel RG (1987) D1e d1abet1sche Nephropath1e. Med Welt 38: 570–576Google Scholar
  21. 21.
    Bretzel RG (1987) Spätkompl1kat1onen des D1abetes mell1tus: Renales Syndrom. Therap1ewoche 37: 4056–4064Google Scholar
  22. 22.
    Bretzel RG (1988) D1abetes mell1tus 1m Vorfeld der N1erenersatztherap1e. 1n: Franz HE (Hrsg) D1alyse 1988. W1ssenschaftl1che Verlagsgesellschaft, Stuttgart, S 141–150Google Scholar
  23. 23.
    Br1chard S, Ketelslegers JM, Lambert AE (1989) Renal funct1on, glycem1c control and per1ndopr1l 1n d1abet1c pat1ents. Cl1n Exp Hypertens1on 11 [suppl 2.]: 545–554Google Scholar
  24. 24.
    Brownlee M, Ceram1 A, Vlassara H (1988) Advanced glycosylat1on end products 1n t1ssue and the b1ochem1cal bas1s of d1abet1c compl1cat1ons. N Engl J Med 318: 1315–1321PubMedGoogle Scholar
  25. 25.
    Canessa M, Adragna N, Solomon HS, Connolly TM, Tosteson DC (1980) 1ncreased sod1um-l1th1um countertransport 1n red cells of pat1ents w1th essent1al hypertens1on. N Engl J Med 302: 772–776Google Scholar
  26. 26.
    Carl1ner NH, Schell1ng JL, Pattersson RR, Okus R, Dav1s M (1965) Th1az1de-and phtalam1d1ne-1nduced hyperglycem1a 1n hypertens1ve pat1ents. JAMA 7: 535–540Google Scholar
  27. 27.
    Chr1stensen CK, Mogensen CE (1985) Effect of ant1hypertens1ve treatment on progress1on of 1nc1p1ent d1abet1c nephropathy. Hypertens1on J [suppl. 2]: 109–113Google Scholar
  28. 28.
    Chr1stl1eb AR, Assal JP, Kats1lambros N, W1ll1ams GH, Kozak GP, Suzuk1 T (1975) Plasma ren1n act1v1ty and blood volume 1n uncontrolled d1abetes: Ketoac1das1s, a state of secondary aldosteron1sm. D1abetes 24: 190–193Google Scholar
  29. 29.
    Chr1stl1eb AR, Jonka HH, Kraus B, Gleason RE, Kasas-Cabral EA, A1ello LM, Cabral BV, Solano A (1976) Vascular react1v1ty to ang1otens1n 2 and to norep1nephr1ne 1n d1abet1c subjects. D1abetes 25: 268–274Google Scholar
  30. 30.
    Chr1stl1eb AR, Kaldany A, D’El1a JA (1976): Plasma ren1n act1v1ty and hypertens1on 1n d1abetes mell1tus. D1abetes 25: 969–974Google Scholar
  31. 31.
    Chr1stl1eb AR, Mak1 PC (1980) The effect of betablocker therapy on glucose and l1p1d metabol1sm. Pr1m Card1ol [suppl.]: 47–54Google Scholar
  32. 32.
    Chr1stl1eb AR, Warram JH, Krolewsk1 AS, Bus1ck EJ, Ganda OP, Asmal AC, Soeldner JS, Bradley RF (1981) Hypertens1on: the major r1sk factor 1n juven1le-onset 1nsul1n-dependent d1abet1cs. D1abetes 30 [suppl. 21: 90–96Google Scholar
  33. 33.
    Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC (1990) 1slet amylo1d polypept1de 1n d1abet1c and non-d1abet1c P1ma 1nd1ans. D1abetolog1a 33: 285–289Google Scholar
  34. 34.
    Clausen T (1986) Regulat1on of act1ve Na+-K+-transport 1n skeletal muscle. Phys1ol Rev 66: 542–580Google Scholar
  35. 35.
    Cox M, Sterns RH, S1nger 1 (1978) The defense aga1nst hyperkal1em1a: the roles of 1nsul1n and aldosterone. N Engl J Med 299: 225–232Google Scholar
  36. 36.
    D’Angelo A, Scartor1 L, Gambaro G, G1ann1n1 S, Malvas1 L, Benetello P, Lavagn1n1 T, Crepald1 G (1986) Captopr1l 1n the treatment of hypertens1on 1n type 1 and type 2 d1abet1c pat1ents. Postgrad Med J 62 [suppl.]: 69–72PubMedGoogle Scholar
  37. 37.
    Dawber TR (1980) D1abetes and Card1ovascular D1sease 1n the Fram1ngham study. Harvard Un1vers1ty Press, Cambr1dge/MA, pp 190–201Google Scholar
  38. 38.
    Day JL, S1mpson N, Metcalfe J, Page RL (1979) Metabol1c consequences of atenolol and propranolol 1n treatment of essent1al hypertens1on. Br Med J 1: 77–80PubMedGoogle Scholar
  39. 39.
    De Chatel R, We1dmann P, Flammer J, Z1egler WH, Beretta-P1ccol1 C, Vetter W, Reub1 FC (1977) Sod1um, ren1n, aldosterone, catecholam1ne and blood pressure 1n d1abetes mell1tus. K1dney 1nt 12: 412–421Google Scholar
  40. 40.
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofold-Enevoldsen A (1989) Album1nur1a reflects w1despread vascular damage. The Steno hypothes1s. D1abetolog1a 32: 219–226Google Scholar
  41. 41.
    De Fronzo RA (1981) The effect of 1nsul1n on renal sod1um metabol1sm. A rev1ew w1th cl1n1cal 1mpl1cat1ons. D1abetolog1a 21: 165–171Google Scholar
  42. 42.
    De Fronzo RA (1988) The tr1umv1rate: B-cell, muscle, l1ver: a collus1on respons1ble for N1DDM. D1abetes 37: 667–687Google Scholar
  43. 43.
    De Fronzo RA, Ferrann1n1 E, Ko1v1sto V (1983) New concepts 1n the pathogenes1s and treatment of non-1nsul1n-dependent d1abetes mell1tus. Am J Med 74 [suppl. 1 Al: 52–81Google Scholar
  44. 44.
    De Lu1se M, Blackburn GL, Fl1er JS (1980) Reduced act1v1ty of the red-cell sod1um-potass1um pump 1n human obes1ty. N Engl J Med 303: 1017–1022Google Scholar
  45. 45.
    Deutsche L1ga zur Bekämpfung des hohen Blutdruckes und Deutsche D1abetes Gesellschaft (1990) Empfehlungen für d1e Behandlung des Hochdruckes be1 D1abetes. D1abetol 1nform 12: 8–14Google Scholar
  46. 46.
    De Wardener HE, MacGregor GA (1983) The relat1on of a c1rculat1ng sod1um transport 1nh1b1tor (the natr1uret1c hormone?) to hypertens1on. Med1c1ne 62: 326–328Google Scholar
  47. 47.
    D1eterle P, Fehm H, Ströder W, Henner J, Bottermann P, Schwarz K (1967) Asymptomat1scher D1abetes mell1tus be1 normalgew1cht1gen Hyperton1kern. Dtsch Med Wochenschr 92: 2376–2381Google Scholar
  48. 48.
    D1etze G (1982) Modulat1on of the act1on of 1nsul1n 1n relat1on to the energy state 1n skeletal muscle t1ssue: poss1ble 1nvolvement of k1n1ns and prostagland1ns. Mol Cell Endocr1nol 25: 127–149Google Scholar
  49. 49.
    D1etze GJ, W1cklmayr M (1977) Effekt von Bradyk1n1n auf d1e Glukoseaufnahme durch d1e Muskulatur be1m Menschen. Kl1n Wochenschr 55: 357–358Google Scholar
  50. 50.
    Dodson PM, Pacy PJ, Bal P, Kub1ck1 AJ, Fletcher RF, Taylor KG (1984) A controlled tr1al of a h1gh f1bre, low fat, and low sod1um d1et for m1ld hypertens1on 1n type 2 (non-1nsul1n-dependent) d1abet1c pat1ents. D1abetolog1a 27: 522–526Google Scholar
  51. 51.
    Donahue RP, Orchard TJ, Becker DJ, Kuller LH, Drash AL (1987) Sex d1fferences 1n the coronary heart d1sease r1sk prof1le: a poss1ble role for 1nsul1n. Am J Ep1dem1ol 125: 650–657Google Scholar
  52. 52.
    Doyle AE, Mart1n FJR, Alford F, Jerums G, Mashford ML, De Lu1se M, Cooper ME (1988) A compar1son of the effects of blood pressure reduct1on w1th per1ndopr1l and n1fed1p1ne on m1croalbum1nur1a 1n hypertens1ve and normotens1ve type 1 and type 2 d1abet1cs. Proceed1ngs Second 1nt. Symp. Hypertens. Assoc. w1th D1abet mell1tus, Par1s, p 40Google Scholar
  53. 53.
    Drummond K, Levy-Marchal C, Laborde K, K1ndermans C, Wr1ght C, Dechaux M, Czern1chow P (1989) Enalapr1l does not alter renal funct1on 1n normotens1ve, normoalbum1nur1c, hyperf1ltrat1ng type 1 (1nsul1n-dependent) d1abet1c ch1ldren. D1abetolog1a 32: 255–260Google Scholar
  54. 54.
    Drury PL (1983) D1abetes and arter1al hypertens1on. D1abetolog1a 24: 1–9Google Scholar
  55. 55.
    Dupree EA, Meyer MB (1981) Role of r1sk factors 1n compl1cat1ons of d1abetes mell1tus. Am J Ep1dem1ol 113: 276–284Google Scholar
  56. 56.
    Ehrl1ch JC, Ratner JM (1961) Amylo1dos1s of the 1slets of Langerhans: a restudy of 1slet hyal1n 1n d1abet1c and non-d1abet1c 1nd1v1duals. Am J Pathol 38: 49–59Google Scholar
  57. 57.
    El1ahou HE, Cohen D, Ben-Dav1d A, Herzog D, Serban J, Gavendo S, Kapuler S, Kogan N, Hellberg B (1988) The calc1um channel blocker n1sold1p1ne delays progress1on of chron1c renal fa1lure 1n humans (prel1m1nary commun1cat1on). Card1ovasc Drug Ther 1: 523–528Google Scholar
  58. 58.
    Ell1ot AH, Mazum FR (1934) The ur1nary excret1on of a depressor substance (Kall1kre1n of Frey and Kraut) 1n arter1al hypertens1on. Endocr1nology 18: 462–464Google Scholar
  59. 59.
    Evans D, Murray R, K1ssebah AH (1984) Relat1onsh1p between skeletal muscle 1nsul1n res1stance, 1nsul1n-med1ated glucose d1sposal and 1nsul1n b1nd1ng: effects of obes1ty and body fat topography. J Cl1n 1nvest 74: 1515–1525Google Scholar
  60. 60.
    Fagard R, M’Buyamba JR, Staessen J, Vanhees L, Amery A (1984) Phys1cal act1v1ty and blood pressure. 1n: Bulg1tt CJ (ed) Handbook of hypertens1on, vol 6: Ep1dem1ology of hypertens1on. Elsev1er, Amsterdam, pp 104–130Google Scholar
  61. 61.
    Feldt-Rasmussen B, Math1esen ER, Deckert T, G1ese J, Chr1stensen MJ, Bent-Hansen L, N1elsen MD (1987) Central role for sod1um 1n the pathogenes1s of blood pressure changes 1ndependent of ang1otens1n, aldosterone and catecholam1nes 1n type 1 (1nsul1n-dependent) d1abetes mell1tus. D1abetolog1a 30: 610–617Google Scholar
  62. 62.
    Ferrann1n1 E, Buzz1gol1 G, Bonadonna R, G1or1co MA, Olegg1n1 M, Graz1ade1 L, Pedr1nell1 R, Brand1 L, Bev1lacqua S (1987) 1nsul1n res1stance 1n essent1al hypertens1on. N Engl J Med 317: 350–357Google Scholar
  63. 63.
    Ferr1ere M, Lachkar H, R1chard JL, Br1nger J, Orsett1 A, M1rouze J (1985) Captopr1l and 1nsul1n sens1t1v1ty. Ann 1ntern Med 102: 134–135Google Scholar
  64. 64.
    F1nott1 P, Palat1n1 P (1986) Reduct1on of erythrocyte (Na +) ATP-ase act1v1ty 1n type 1 (1nsul1n-dependent) d1abet1c subjects and 1ts act1vat1on by homologous plasma. D1abetolog1a 29: 623–628Google Scholar
  65. 65.
    Flapan A, Na1r JM, Padf1eld PL (1988) Does captopr1l protect aga1nst d1uret1c-1nduced 1mpa1rment of glucose tolerance? Cl1n Sc1 72 [suppl. 161: 73–74Google Scholar
  66. 66.
    Florey CV, Uppal S, Lowy C (1976) Relat1on between blood pressure, we1ght and plasma sugar and serum 1nsul1n levels 1n school ch1ldren aged 9–12 years 1n Westland, Holland. Br Med J 1: 1368–1371PubMedGoogle Scholar
  67. 67.
    Fr1ck MH, Elo O, Haapa K, He1nonen OP, He1nsalm1 P, Helo P, Huttunen JK, Ka1tan1em1 P, Kosk1nen P, Mann1nen V, Mäenpää H, Mälkönen M, Mänttär1 M, Norola S, Pasternack A, P1kkara1nen J, Romo M, Sjöblom T, N1kk1lä EA (1987) Hels1nk1 Heart Study: pr1mary prevent1on tr1al w1th gemf1broz1l 1n m1ddle-aged men w1th dysl1p1dem1a. Safety of treatment, changes 1n the r1sk factors, and 1nc1dence of coronary heart d1sease. N Engl J Med 317: 1237–1245PubMedGoogle Scholar
  68. 68.
    Fuller JH (1985) Ep1dem1ology of hypertens1on assoc1ated w1th d1abetes mell1tus. Hypertens1on 7 [suppl. 21: 23–2 7Google Scholar
  69. 69.
    Fuller JH, Sh1pley MJ, Rose G, Jarrett RJ, Keen H (1980) Coronary-heart-d1sease r1sk and 1mpa1red glucose tolerance: the Wh1tehall study. Lancet 1: 1373–1376PubMedGoogle Scholar
  70. 70.
    Garc1a MJ, McNamara PM, Gordon T, Kannel WB (1974) Morb1d1ty and mortal1ty 1n d1abet1cs 1n the Fram1ngham populat1on. S1xteen year follow-up study. D1abetes 23: 105–111Google Scholar
  71. 71.
    Gav1n JR, Roth J, Nev1le DM, De Meyts P, Buell DN (1975) 1nsul1n-dependent regulat1on of 1nsul1n receptor concentrat1ons: a d1rect demonstrat1on 1n cell culture. Proc Natl Acad Sc1 USA 71: 84–88Google Scholar
  72. 72.
    Gw1nup G, El1as AN (1990) 1nsul1n as r1sk factor for vascular d1sease. D1abetes Care 13: 543–545Google Scholar
  73. 73.
    Hanefeld M, Schulze J, F1scher S, Jul1us U, Schmechel H, Haller H (1985) The D1abetes 1ntervent1on Study (D1S): a cooperat1ve mult2ntervent1on tr1al w1th newly man1fested type-2 d1abet1cs: prel1m1nary results. Monogr Atheroscler 13: 98–103PubMedGoogle Scholar
  74. 74.
    Hay U, Ludv1k B, G1s1nger CH, Schernthaner G (1988) Fehlender Effekt der ACE-1nh1b1t1on auf d1e Makroprote1nur1e be1 d1abet1scher Nephropath1e — e1ne Langze1tstud1e über 6 Monate. Schwe1z med Wochenschr 118: 165–169Google Scholar
  75. 75.
    Helgeland A (1980) Treatment of m1ld hypertens1on: a f1ve year controlled drug tr1al: the Oslo study. Am J Med 69: 725–732PubMedGoogle Scholar
  76. 76.
    Helgeland A, Hagelund CH, Strommen R, Tretl1 S (1986) Enalapr1l, atenolol and hydrochloroth1az1de 1n m1ld to moderate hypertens1on. A comparat1ve mult1center study 1n general pract1ce 1n Norway. Lancet 1: 872–875PubMedGoogle Scholar
  77. 77.
    H1lton PJ (1986) Cellular sod1um transport 1n essent1al hypertens1on. N Engl J Med 314: 222–229PubMedGoogle Scholar
  78. 78.
    Holm G, Herl1tz J, Sm1th U (1981) Severe hypoglycem1a dur1ng phys1cal exerc1se and treatment w1th beta-blockers. Br Med J 282: 13–60Google Scholar
  79. 79.
    Hommel E, Math1esen E, Edsberg B, Bahnsen M, Parv1ng H-H (1986) Acute reduct1on of arter1al blood pressure reduces ur1nary album1n excret1on 1n type 1 (1nsul1n-dependent) d1abet1c pat1ents w1th 1nc1p1ent nephropathy. D1abetolog1a 29: 211–215Google Scholar
  80. 80.
    Hommel E, Parv1ng H-H, Math1esen E, Edsberg B, Damkjaer N1elsen M, G1ese J (1986) Effect of captopr1l on k1dney funct1on 1n 1nsul1n-dependent d1abet1c pat1ents w1th nephropathy. Br Med J 293: 467–470Google Scholar
  81. 81.
    Hostetter TH, Rennke HG, Brenner BM (1982) The case of 1ntrarenal hypertens1on 1n the 1n1t1at1on and progress1on of d1abet1c and other glomerulopath1es. Am J Med 72: 375–380PubMedGoogle Scholar
  82. 82.
    Hwang 1S, Ho H, Hoffmann BB, Reaven GM (1987) Fructose-1nduced 1nsul1n res1stance and hypertens1on 1n rats. Hypertens1on 10: 512–516Google Scholar
  83. 83.
    Hypertens1on Detect1on and Follow-up Program Cooperat1ve Group (1979) F1ve year f1nd1ngs of the hypertens1on detect1on and follow-up program: reduct1on 1n mortal1ty of persons w1th h1gh blood pressure, 1nclud1ng m1ld hypertens1on. JAMA 242: 2562–2571Google Scholar
  84. 84.
    nsua A, R1bste1n J, M1mran A (1988) Comparat1ve effect of captopr1l and n1fed1p1ne 1n normotens1ve pat1ents w1th 1nc1p1ent d1abet1c nephropathy. Postgrad Med J 64 suppl 3: 59–62Google Scholar
  85. 85.
    Jahnke K (1990) Grundlagen der Ernährung and D1ätempfehlungen für D1abet1ker (Stellungnahme der Deutschen D1abetes Gesellschaft). Aktuel Ernährungsmed 15: 27–38Google Scholar
  86. 86.
    Janka HU (1988) 1nfluence of calc1um antagon1sts on hemorheology. 1n: Gr1es FA, We1dmann P (eds) D1abetes and hypertens1on. Spr1nger, Berl1n He1delberg New York Tokyo, pp 69–73Google Scholar
  87. 87.
    Jarrett RJ, Keen H, McCartney M, Fuller GM, Ham1lton PJ, Re1d DD, Rose G (1978) Glucose tolerance and blood pressure 1n two populat1on samples: the1r relat1on to d1abetes mell1tus and hypertens1on. 1nt J Ep1dem1ol 7: 15–24Google Scholar
  88. 88.
    Jauch KW, Günther B, Harte W, Rett K, W1cklmayr M, D1etze G (1986) 1mprovement of 1mpa1red postoperat1ve 1nsul1n act1on by bradyk1n1n. Hoppe-Seylers Z B1ol Chem 367: 207–210Google Scholar
  89. 89.
    Jenn1ngs G, Nelson L, Mertel P, Esler M, Korner P, Burton D, Bazelmans J (1986) The effects of changes 1n phys1cal act1v1ty on major card1ovascular r1sk factors, hemodynam1cs, sympathet1c funct1on, and glucose ut1l1zat1on 1n man: a controlled study of four levels of act1v1ty. C1rculat1on 73: 30–40Google Scholar
  90. 90.
    Johnson KH, O’Br1en TD, Jordan K, Westermark P (1989) 1mpa1red glucose tolerance 1s assoc1ated w1th 1ncreased 1slet amylo1d polypept1de (1APP) 1mmunoreact1v1ty 1n pancreat1c beta cells. Am J Pathol 135: 245–250Google Scholar
  91. 91.
    Jourdheu1l RA, Monra1re J, Vague P, Boyer J, Juhan-Vague J (1987) 1n v1vo 1nsul1n effect on ATP-ase act1v1t1es 1n erythrocyte membrane from 1nsul1n-dependent d1abet1cs. D1abetes 36: 991–995Google Scholar
  92. 92.
    Jungmann E, Höll E, Konzok C, Sch1rmer U, Walter-Schräder M-C, Althoff P-H, Schöffl1ng K (1988) Med Kl1n 83: 325–326Google Scholar
  93. 93.
    Jungmann E, Schumann-Draeger P-M, Sch1fferdecker E, N1ckelsen T, Scheuermann E-H, Schöffl1ng K (1989) Zum E1nsatz von Felod1p1n, e1nem neueren Calc1umantagon1sten, 1n der ant1hypertens1ven Therap1e von Pat1enten m1t D1abetes mell1tus. Kl1n Wochenschr 67 [suppl. 161: 242 (Abstract)Google Scholar
  94. 94.
    Kahn SE, D’Aless1o DA, Schwartz MW, Fuj1moto WY, Ens1nck JW, Taborsky GJ jr, Porte D jr (1990) Ev1dence of cosecret1on of 1slet amylo1d polypept1de and 1nsul1n by beta-cells. D1abetes 39: 634–638Google Scholar
  95. 95.
    Keen H (1987) The bad compan1ons. 19th Claude Bernard Lecture, 23th Annual Meet1ng of the EASD, Le1pz1gGoogle Scholar
  96. 96.
    Kelleher C, K1ngston SM, Barry DG, Cole MM, Ferr1s JB, Grealy G, Joyce C, O’Sull1van DJ (1988) Hypertens1on 1n d1abet1c cl1n1c pat1ents and the1r s1bl1ngs. D1abetolog1a 31: 76–81Google Scholar
  97. 97.
    Kendall MJ, Lew1s H, Gr1ff1th M, Barnett AH (1988) Drug treatment of the hypertens1ve d1abet1c. J Hum Hypertens 1: 249–258PubMedGoogle Scholar
  98. 98.
    K1ssebah AH, Vydel1ngum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW (1982) Relat1on of body-fat d1str1but1on to metabol1c compl1cat1ons of obes1ty. J Cl1n Endocr1nol Metab 54: 254–260Google Scholar
  99. 99.
    Klaus D (1990) Hochdruckbehandlung 1n der Prax1s. Dtsch Ärztebl 87: 1238–1243Google Scholar
  100. 100.
    Kostner GM, Karad1 J (1988) L1poprote1n alterat1ons 1n d1abetes mell1tus. D1abetolog1a 31: 717–722Google Scholar
  101. 101.
    Krolewsk1 AS, Canessa N, Warram JH, Laffel L, Chr1stl1eb R, Knowler WC, Rand LJ (1988) Pred1spos1t1on to hypertens1on and suscept1b1l1ty to renal d1sease 1n 1nsul1n-dependent d1abetes mell1tus. N Engl J Med 318: 140–145PubMedGoogle Scholar
  102. 102.
    Krone W, Nägele H, Müller-W1eland D (1989) Bee1nflussung des Fettstoffwechsels durch Ant1hypertens1va. 1n: Schrör K, Ohlrogge R (Hrsg) Calc1umantagon1sten und Atherosklerose. Med1kon, München, S66–76Google Scholar
  103. 103.
    Krotk1ewsk1 M, Mandroukas K, Sjonstrom L, Sull1van L, Welterqu1st H, Björntorp P (1979) Effects of long-term phys1cal tra1n1ng on body fat, metabol1sm, and blood pressure 1n obes1ty. Metabol1sm 28: 650–658Google Scholar
  104. 104.
    Lager J, Blohme G, Sm1th U (1979) Effect of card1oselect1ve and non-select1ve beta-blockade on the hypoglycem1c response 1n 1nsul1n-dependent d1abet1cs. Lancet 1: 455–462Google Scholar
  105. 105.
    Lanza G, Barbera R, Fontana S (1985) Treatment of hypertens1on 1n the d1abet1c w1th captopr1l. M1nerva Med 11: 183–184Google Scholar
  106. 106.
    Lasser NL, Grand1ts G, Cagg1ula AW, Cutler JA, Gr1mm RH Jr, Kuller LH, Sherw1n RW, Stamler J (1984) Effects of ant1hypertens1ve therapy on plasma l1p1ds and l1poprote1ns 1n the Mult1ple R1sk Factor 1ntervent1on Tr1al. Am J Med 76 (2a): 52–66PubMedGoogle Scholar
  107. 107.
    Le1ghton B, Cooper GJS (1988) Pancreat1c amyl1n and calc1ton1n gene related pept1de (CGRP) causes res1stance to 1nsul1n 1n skeletal muscle 1n v1tro. Nature 335: 632–635PubMedGoogle Scholar
  108. 108.
    L1ebau H, Wurst W, Harder J, Solleder P (1988) Stoffwechselneutrale Hochdrucktherap1e. Offene, mult1zentr1sche, prospekt1ve Langze1tprüfung von Verträgl1chke1t, S1cherhe1t and W1rksamke1t von Urap1d1l. Fortschr Med 106: 651–654PubMedGoogle Scholar
  109. 109.
    L1p1d Research Cl1n1cs Program (1984) The l1p1d research cl1n1cs coronary pr1mary prevent1on tr1al results. 1. Reduct1on 1n 1nc1dence of coronary heart d1sease. JAMA 251: 351–364Google Scholar
  110. 110.
    L1pson LG (1984) Treatment of hypertens1on 1n d1abet1c men: problems w1th sexual dysfunct1on. Am J Card1ol 53: 46–50Google Scholar
  111. 111.
    MacMahon SW, MacDonald GJ, Bernste1n L, Andrews G, Blacket RB (1985) Compar1son of we1ght reduct1on w1th metaprolol 1n treatment of hypertens1on 1n young overwe1ght pat1ents. Lancet 1: 1233–1236PubMedGoogle Scholar
  112. 112.
    Major SG (1929) Blood pressure 1n d1abetes mell1tus: a stat1st1cal study. Arch 1ntern Med 44: 797–812Google Scholar
  113. 113.
    Maranon G (1922) Über Hyperton1e and Zuckerkrankhe1t. Z 1nn Med 43: 169–176Google Scholar
  114. 114.
    Marble A (1974) The natural h1story of d1abetes. Horm Metabol Res 6 [suppl. 4]: 153–158Google Scholar
  115. 115.
    Margol1us HS, Geller R, P1sano JJ, Sjoerdsma A (1971) Altered ur1nary Kall1kre1n excret1on 1n human hypertens1on. Lancet 2: 1063–1065Google Scholar
  116. 116.
    Marre M, Chatell1er G, Leblanc H, Guyenne T-T, Menard J, Passa P (1988) Prevent1on of d1abet1c nephropathy w1th enalapr1l 1n normotens1ve d1abet1cs w1th m1croalbum1nur1a. Br Med J 297: 1086–1091Google Scholar
  117. 117.
    Marre M, Leblanc H, Suarez L, Guyenne T-T, Menard J, Passa P (1987) Convert1ng enzyme 1nh1b1t1on and k1dney funct1on 1n normotens1ve d1abet1c pat1ents w1th pers1stent m1croalbum1nur1a.’Br Med J 294: 1448–1452Google Scholar
  118. 118.
    Marshall S, Olefsky J (1980) Effects of 1nsul1n 1ncubat1on on 1nsul1n b1nd1ng, glucose transport, and 1nsul1n degradat1on by 1solated rat ad1pocytes. Ev1dence of hormone-1nduced desens1t1zat1on at the receptor and post-receptor level. J Cl1n 1nvest 66: 763–772Google Scholar
  119. 119.
    Math1esen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T (1984) 1nc1p1ent nephropathy 1n type 1 (1nsul1n-dependent) d1abetes. D1abetolog1a 26: 406–410Google Scholar
  120. 120.
    Matthews DM, Wathen CG, Bell D, Coll1er A, Mu1r AL, Clarke BF (1986) The effect of captopr1l on blood pressure and glucose tolerance 1n hypertens1ve non-1nsul1n dependent d1abet1cs. Postgrad Med J 62 [suppl. 1]: 73–75PubMedGoogle Scholar
  121. 121.
    Mau Pedersen M, Schm1tz A, Pedersen EB, Dan1elsen H, Chr1st1ansen JS (1988) Acute and long-term renal effects of ang1otens1n convert1ng enzyme 1nh1b1t1on 1n normotens1ve, normoalbum1nur1c 1nsul1n-dependent d1abet1c pat1ents. D1abet1c Med 5: 562–569Google Scholar
  122. 122.
    Med1cal Research Counc1l Work1ng Party on M1ld to Moderate Hypertens1on (1981) Adverse react1ons to bendrofluaz1de and propranolol for the treatment of m1ld hypertens1on. Lancet 2: 539–543Google Scholar
  123. 123.
    Med1cal Research Counc1l Work1ng Party (1985) MRC tr1al of treatment of m1ld hypertens1on: pr1nc1pal results. Br Med J 291: 97–104Google Scholar
  124. 124.
    M1mran A, 1nsua A, R1bste1n J, Mon1er L, Br1nger J, M1rouze J (1988) Contrast1ng effects of captopr1l and n1fed1p1ne 1n normotens1ve pat1ents w1th 1nc1p1ent d1abet1c nephropathy. J Hypertens1on 6: 919–923Google Scholar
  125. 125.
    Modan M, Halk1n H, Almog S, Lusky A, Eskol A, Shef1 M, Sh1tr1t A, Fuchs L (1985) Hyper1nsul1naem1a. A l1nk between hypertens1on, obes1ty and glucose tolerance. J Cl1n 1nvest 75: 809–817Google Scholar
  126. 126.
    Mogensen CE (1976) Progress1on of nephropathy 1n longterm d1abet1cs w1th prote1n-ur1a and effect of 1n1t1al ant1-hypertens1ve treatments. Scand J Cl1n Lab 1nvest 36: 383–388Google Scholar
  127. 127.
    Mogensen CE (1982) Long-term ant1hypertens1ve treatment 1nh1b1t1ng progress1on of d1abet1c nephropathy. Br Med J 285: 685–688Google Scholar
  128. 128.
    Mogensen CE (1984) M1croalbum1nur1a pred1cts cl1n1cal prote1nur1a and early mortal1ty 1n matur1ty-onset-d1abetes. N Engl J Med 310: 356–360PubMedGoogle Scholar
  129. 129.
    Mogensen CE, Chr1stensen CK (1984) Pred1ct1ng d1abet1c nephropathy 1n 1nsul1n-dependent pat1ents. N Engl J Med 311: 89–93PubMedGoogle Scholar
  130. 130.
    Mogensen CE, Chr1stensen CK (1985) Blood pressure changes and renal funct1on 1n 1nc1p1ent and overt d1abet1c nephropathy. Hypertens1on 7 [suppl. 2]: 264–273Google Scholar
  131. 131.
    Mogensen CE, Chr1stensen CK, Beck-N1elsen H, V1tt1nghus E (1983) Early changes 1n k1dney funct1on, blood pressure and the stages 1n d1abet1c nephropathy. 1n: Keen H, Legra1n M (eds) D1abet1c nephropathy. MTP Press, Lancaster, pp 57–83Google Scholar
  132. 132.
    Mogensen CE, Chr1stensen CK, Chr1st1ansen JS, Beck-N1elsen H (1986) On pred1ct1ng and prevent1ng d1abet1c nephropathy. 1n: Fr1edmann EA, L’Esperance EA jr (eds) D1abet1c renal-ret1nal syndrome, vol 3. Grune and Stratton, New York, pp 81–109Google Scholar
  133. 133.
    Morell1 E, Loom N, Meyer T, Peters W, Myers BD (1990) Effects of convert1ng enzyme 1nh1b1t1on on barr1er funct1on 1n d1abet1c glomerulopathy. D1abetes 39: 76–82Google Scholar
  134. 134.
    MRC Tr1al (1981) Report of Med1cal Research Counc1l Work1ng Party on m1ld to moderate hypertens1on. Adverse react1ons to bendrofluaz1de and propranolol for the treatment of m1ld hypertens1on (1981). Lancet 2: 539–542Google Scholar
  135. 135.
    Murphy MB, Lew1s PJ, Kohner E, Schumer B, Dollery CT (1982) Glucose 1ntolerance 1n hypertens1ve pat1ents treated w1th d1uret1cs: a fourteen-year follow-up. Lancet 2: 1293–1295PubMedGoogle Scholar
  136. 136.
    Ng LL, Dudley C, Bomford J, Hawley D (1989) Leucocyte 1ntracellular pH and Na +/H ant1post act1v1ty 1n human hypertens1on. J Hypertens1on 7: 471–475Google Scholar
  137. 137.
    N1kk1la EA, Verenna MR, M1ett1nen TA, Pelkonen R (1965) Plasma-1nsul1n 1n coronary heart d1sease. Lancet 2: 508–511PubMedGoogle Scholar
  138. 138.
    Norgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Slaelan H, Deckert T (1990) Prevalence of hypertens1on 1n Type 1 (1nsul1n-dependent) d1abetes mel1tus. D1abetolog1a 33: 407–410Google Scholar
  139. 139.
    Nyberg G, Blohme G, Björck S (1984) Progress1on of d1abet1c nephropathy 1n relat1on to plasma glucose control and blood pressure control. D1abet1c Nephropathy 4: 53–54Google Scholar
  140. 140.
    Od1gwe CO, McCulloch AJ, W1ll1ams DO, Tunbr1dge WMGC (1986) A tr1al of the calc1um antagon1te n1sold1p1ne 1n hypertens1ve non-1nsul1n-dependent d1abet1c pat1ents. D1abet1c Med 3: 463–467Google Scholar
  141. 141.
    Oestman J (1983) Beta-adrenerg1c blockade and d1abetes mell1tus. Acta Med Scand 672 [suppl.]: 62–77Google Scholar
  142. 142.
    Op1e EL (1900) On the relat1on of chron1c 1nterst1t1al pancreat1t1s to the 1slands of Langerhans and to d1abetes mell1tus. J Exp Med 5: 397–428Google Scholar
  143. 143.
    Ostlund RE jr, Slemenkov1ch CF, Schechtman KB (1989) Quant1tat1ve relat1onsh1p between plasma l1p1ds and glycohemoglob1n 1n type 1 pat1ents: long1tud1nal study of 212 pat1ents. D1abetes Care 12: 332–336Google Scholar
  144. 144.
    Pacy PJ, Dodson PM (1985) Nutr1t1on and hypertens1on. Ann Nutr Metab 25: 129–137Google Scholar
  145. 145.
    Pacy PJ, Dodson PM, Fletcher RF (1986) Effect of a h1gh carbohydrate, low sod1um, and low fat d1et 1n type 2 d1abet1cs w1th moderate hypertens1on. 1nt J Obes1ty 10: 43–52Google Scholar
  146. 146.
    Panzram G, Zabel-Langhenn1ng R (1984) D1abetes mell1tus: Bed1ngte Gesundhe1t oder sch1cksalhafte Erkrankung? Med Prax1s 79: 27–37Google Scholar
  147. 147.
    Paol1sso G, Passer1ello M, Sgambato JS, Torecca R, Buon1ncont1 R, Varr1cch1o M, D’Onofr1o F (1987) 1mpa1red 1nsul1n-med1ated erythrocyte magnes1um accumulat1on 1n essent1al hypertens1on. Cl1n Sc1 73: 535–539Google Scholar
  148. 148.
    Parv1ng HH, Anderssen AR, Schm1dt UM, Svendsen PA (1983) Early aggress1ve ant1-hypertens1ve treatment reduces rate of decl1ne 1n k1dney funct1on 1n d1abet1c nephropathy. Lancet 1: 1175–1179PubMedGoogle Scholar
  149. 149.
    Parv1ng H-H, Andersen AR, Sm1dt U, Sandahl-Chr1st1ansen J, Oxenboll B, Svendsen PA (1983) D1abet1c nephropathy and arter1al hypertens1on. The effect of ant1hypertens1va treatment. D1abetes 32 [suppl. 21: 83–87Google Scholar
  150. 150.
    Parv1ng HH, Hommel E, Math1esen E, Skott P, Edsberg B, Bahnsen M, Laur1tzen M, Hongaard P, Laur1tzen E (1988) Prevalence of m1croalbum1nur1a, arter1al hypertens1on, ret1nopathy and neuropathy 1n pat1ents w1th 1nsul1n dependent d1abetes. Br Med J 296: 156–160Google Scholar
  151. 151.
    Parv1ng H-H, Hommel E, Schm1dt UM (1988) Protect1on of k1dney funct1on and decrease 1n album1nur1a by captopr1l 1n 1nsul1n dependent d1abet1cs w1th nephropathy. Br Med J 297: 1086–1091Google Scholar
  152. 152.
    Parv1ng HH, Oxenboll B, Svendsen PA, Sandahl-Chr1st1ansen J, Andersen AR (1982) Early detect1on of pat1ents at r1sk of develop1ng d1abet1c nephropathy. A long1tud1nal study of ur1nary album1n excret1on. Acta Endocr1nol 100: 550–555Google Scholar
  153. 153.
    Passa Ph, Marre M, Leblanc H (1986) Enalapr1l, Captopr1l and blood glucose. Lancet 1: 14–47Google Scholar
  154. 154.
    Passa P, Marre M, Menard J (1988) One year effect of enalapr1l 1n d1abet1c pat1ents w1th m1croalbum1nur1a and no hypertens1on. D1abetes Metab 14: 230–231Google Scholar
  155. 155.
    Pell S, D’Alonzo CA (1967) Some aspects of hypertens1on 1n d1abetes mell1tus. JAMA 202: 104–110PubMedGoogle Scholar
  156. 156.
    Pett1tt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC (1990) Fam1l1al pred1spos1t1on to renal d1sease 1n two generat1ons of P1ma 1nd1ans w1th type 2 (non-1nsul1ndependent) d1abetes mell1tus. D1abetolog1a 33: 438–443Google Scholar
  157. 157.
    Pollare T, L1thell H, Berne C (1989) A compar1son of the effects of hydrochloroth1az1de and captopr1l on glucose and l1p1d metabol1sm 1n pat1ents w1th hypertens1on. N Engl J Med 321: 868–873PubMedGoogle Scholar
  158. 158.
    Pollare T, L1thell H, Sel1nus J, Berne C (1988) Appl1cat1on of prazos1n 1s assoc1ated w1th an 1ncrease of 1nsul1n sens1t1v1ty 1n obese pat1ents w1th hypertens1on. D1abetolog1a 31: 415–420Google Scholar
  159. 159.
    Pollare T, L1thell H, Sel1nus J, Berne C (1989) Sens1t1v1ty to 1nsul1n dur1ng treatment w1th atenolol and metoprolol: a random1zed, double bl1nd study of effects on carbohydrate and l1poprote1n metabol1sm 1n hypertens1ve pat1ents. Br Med J 298: 1152–1157Google Scholar
  160. 160.
    Porte DJR, Kahn SE (1989) Hyperpro1nsul1nem1a and amylo1d 1n N1DDM: clues to et1ology of 1slet beta-cell dysfunct1on. D1abetes 38: 1333–1336Google Scholar
  161. 161.
    Pyörälä K (1979) Relat1onsh1p of glucose tolerance and plasma 1nsul1n to the 1nc1dence of coronary heart d1sease: results from two populat1on stud1es 1n F1nland. D1abetes Care 2: 131–141Google Scholar
  162. 162.
    Pyörälä K, Laakso M, Uus1tupa M (1987) D1abetes and atheroscleros1s: an ep1dem1olog1c v1ew. D1abetes Metab Rev 3: 463–524Google Scholar
  163. 163.
    Reaven GM (1988) Bant1ng Lecture 1988: Role of 1nsul1n res1stance 1n human d1sease. D1abetes 37: 1595–1607Google Scholar
  164. 164.
    Reaven PD, Barrett-Connor EL, Browner DK (1990) Abnormal glucose tolerance and hypertens1on. D1abetes Care 13: 119–125Google Scholar
  165. 165.
    Re1s1n E, Abel R, Modan M, S1lberberg DS, El1ahon HE, Modan B (1978) Effect of we1ght loss w1thout salt restr1ct1on on the reduct1on of blood pressure 1n overwe1ght hypertens1ve pat1ents. N Engl J Med 298: 1–6PubMedGoogle Scholar
  166. 166.
    Resn1ck LM (1989) Hypertens1on and abnormal glucose homeostas1s. Poss1ble role of d1valent 1on metabol1sm. Am J Med 87 [suppl. 6A]: 17–22Google Scholar
  167. 167.
    Rett K, D1etze G, W1cklmayr M, Mehnert H (1990) Neue Aspekte zur Behandlung der Hyperton1e. MMW 132: 223–225Google Scholar
  168. 168.
    Rett K, Jauch KW, W1cklmayr M, D1etze G, F1nk E, Mehnert H (1986) Ang1otens1n convert1ng enzyme 1nh1b1tors 1n d1abetes: exper1mental and human exper1ence. Postgrad Med J 62 [suppl. 1]: 59–64PubMedGoogle Scholar
  169. 169.
    Rett K, Lotz M, W1cklmayr M, F1nk E, D1etze D (1988) Verbesserte 1nsul1nw1rkung durch ACE-Hemmung be1m Typ 2 D1abet1ker. Dtsch Med Wochenschr 113: 243–249PubMedGoogle Scholar
  170. 170.
    Rett K, W1cklmayer M, D1etze G, Mehnert H (1990) Cl1n1cal stud1es w1th CE-1nh1b1tors 1n d1abetes. Horm Metab Res [suppl. 22]: 69–74Google Scholar
  171. 171.
    Rett K, W1cklmayr M, Tschollar W, D1etze G, Mehnert H (1988) Role of ang1otens1n convert1ng enzyme 1nh1b1tors 1n early ant1hypertens1ve treatment 1n non-1nsul1n dependent d1abetes mell1tus. Postgrad Med J 64 [suppl. 3]: 69–74PubMedGoogle Scholar
  172. 172.
    R1zza RA, Mandar1no LJ, Genst J, Baker BA, Ger1ch JE (1985) Product1on of 1nsul1n res1stance by hyper1nsul1naem1a 1n man. D1abetolog1a 28: 70–75Google Scholar
  173. 173.
    Romanell1 G, G1ust1na A, C1m1no A, Valent1n1 U, Agab1t1ose1 E, Mu1esan G, G1ust1na G (1989) Short term effect of captopr1l on m1croalbum1nura 1nduced by exerc1se 1n normotens1ve d1abet1cs. Br Med J 298: 284–288Google Scholar
  174. 174.
    Rowe JW, Young JB, M1naker KL, Stevens AL, Pallotta J, Landsberg L (1981) Effect of 1nsul1n and glucose 1nfus1ons on sympathet1c nervous system act1v1ty 1n normal man. D1abetes 30: 219–225Google Scholar
  175. 175.
    Rudberg S, Aper1a A, Freyschuss U, Persson B (1990) Enalapr1l reduces m1croalbum1nur1a 1n young normotens1ve type 1 (1nsul1n-dependent) d1abet1c pat1ents 1rrespect1ve of 1ts hypotens1ve effect. D1abetolog1a 33: 470–476Google Scholar
  176. 176.
    Saudeck CD, Boulter PR, Knopp RH, Arkay RA (1974) Sod1um retent1on accompany1ng 1nsul1n treatment of d1abetes mell1tus. D1abetes 23: 240–246Google Scholar
  177. 177.
    Seaqu1st E, Goetz F, R1ch S, Barbosa J (1989) Fam1l1al cluster1ng of d1abet1c k1dney d1sease: ev1dence for genet1c suscept1b1l1ty to d1abet1c nephropathy. N Engl J Med 320: 1161–1165PubMedGoogle Scholar
  178. 178.
    Shen DC, She1h SM, Fuh M, Chen YD, Reaven GM (1988) Res1stance to 1nsul1n-st1mulated glucose uptake 1n pat1ents w1th hypertens1on. J Cl1n Endocr1nol Metab 66: 580–583Google Scholar
  179. 179.
    Sh1onor1 H, M1yakawa T, Takasak1 J, 1sh1kawa Y, H1roto S, Kaneko Y, Sh1ndo Y (1987) Glucose tolerance dur1ng chron1c captopr1l therapy 1n pat1ents w1th essent1al hypertens1on. J Card1ovasc Pharm 9: 160–164Google Scholar
  180. 180.
    S1monson DC (1988) Et1ology and prevalence of hypertens1on 1n d1abet1c pat1ents. D1abetes Care 11: 821–827Google Scholar
  181. 181.
    S1nger P, God1cke W, Vo1gt S, Hajdu 1, We1ss M (1985) Postprand1al hyper1nsul1nem1a 1n pat1ents w1th m1ld essent1al hypertens1on. Hypertens1on 7: 182–186Google Scholar
  182. 182.
    Skarfors ET, L1thell HO, Sel1nus J, Aberg H (1989) Do ant1hypertens1ve drugs prec1p1tate d1abetes 1n pred1sposed men? Br Med J 298: 1147–1152Google Scholar
  183. 183.
    Sprafka JM, Bender AP, Jasser HG (1988) Prevalence of hypertens1on and assoc1ated r1sk factors among d1abet1c 1nd1v1duals The Three-C1ty Study. D1abetes Care 11: 17–22Google Scholar
  184. 184.
    Stamler R, Stamler J, Gr1mm R, Gosch CF, Elmer P, Dyer A, Berman R, F1shman J, Van Heel N, C1v1nell1 J, McDonald A (1987) Nutr1t1onal therapy for h1gh blood pressure: f1nal report of a four-year random1zed control tr1al — the hypertens1on control program. JAMA 257: 1485–1491Google Scholar
  185. 185.
    Stange EF (1989) Atherosklerose be1 D1abetes mell1tus. 1ntern1st 30: 297–303Google Scholar
  186. 186.
    Stout RW (1985) Hyper1nsul1naem1a — a poss1ble r1sk factor for card1ovascular d1sease 1n d1abetes mell1tus. Horm Metab Res 15: 37–41Google Scholar
  187. 187.
    Stout RW (1990) 1nsul1n and atheroma. 20-yr perspect1ve. D1abetes Care 13:631–654Google Scholar
  188. 188.
    Stout RW, Vallance-Owen J (1969) 1nsul1n and atheroma. Lancet 1: 1078–1080Google Scholar
  189. 189.
    Sw1slock1 A, Hoffmann B, Reaven G (1989) 1nsul1n res1stance, glucose 1ntolerance and hyper1nsul1nem1a 1n pat1ents w1th hypertens1on. Am J Hypertens1on 2: 419–423Google Scholar
  190. 190.
    Taguma Y, K1tamoto Y, Futak1 G, Ueda H, Mor1ma H, 1sh1zak1 M, Takahash1 H, Sek1no H, Sasak1 Y (1985) Effect of Enaptopr1l on heavy prote1nur1a 1n azotem1c d1abet1cs. N Engl J Med 313: 1617–1620PubMedGoogle Scholar
  191. 191.
    Tanaka M, Sakaguch1 S, Osh1ge K, N2mura T, Kanch1sa T (1976) Effect of chron1c adm1n1strat1on of propanolol on l1poprote1n compos1t1on. Metabol1sm 25: 1071–1075Google Scholar
  192. 192.
    Taylor SH, Gr1mm RH Jr (1990) New developments 1n the role of al-adrenerg1c receptors 1n card1ovascular d1sease. Am Heart J 119: 655–662Google Scholar
  193. 193.
    Trost BN (1990) glucose metabol1sm and calc1um antagon1sts. Horm Metab Res [suppl. 22]:49–56Google Scholar
  194. 194.
    Trost BN, We1dmann P (1984) Effects of n1trend1p1ne and other calc1um antagon1sts on glucose metabol1sm 1n man. J Card1ovasc Pharmacol 6: 986–995Google Scholar
  195. 195.
    Trost BN, We1dmann P (1987) Effects of calc1um antagon1sts on glucose homeostas1s and serum l1p1ds 1n non-d1abet1c and d1abet1c subjects: a rev1ew. J Hypertens1on 5 [suppl. 4]: 81–104Google Scholar
  196. 196.
    Trost BN, We1dmann P, Beretta-P1ccol1 C (1985) Ant1hypertens1ve therapy 1n d1abet1c pat1ents. Hypertens1on 7: 102–108Google Scholar
  197. 197.
    Turner RC (1985) Un1ted K1ngdom prospect1ve d1abetes survey. 21. Prevalence of hypertens1on and hypotens1ve therapy 1n pat1ents w1th newly d1agnosed d1abetes. Hypertens1on 7 [suppl. 21: 8–13Google Scholar
  198. 198.
    Ueda K, Kuwaj1ma J, 1to H, Kuramoto K, Murakam1 M (1979) N1fed1p1ne 1n the management of hypertens1on. 1n: L1chtlen PR, K1mura E, Ta1ra N (eds) 1nternat1onal n1fed1p1ne (adalat) panel d1scuss1on, Tokyo. Excerpta Med, Amsterdam, pp 105–114Google Scholar
  199. 199.
    Valvo E, Bedogna V, Casagrande P, Ant1ga L, Zambon1 M, Bommart1n1 F, Oldr1zz1 L, Rug1n C, Masch1o G (1988) Captopr1l 1n pat1ents w1th type 2 d1abetes and renal 1nsuff1c1ency: system1c and renal hemodynam1c alterat1ons. Am J Med 85: 344–348PubMedGoogle Scholar
  200. 200.
    Veterans Adm1n1strat1on Cooperat1ve Study Group on Ant1hypertens1ve Agents (1967) Effects of treatment on morb1d1ty 1n hypertens1on: results 1n pat1ents w1th d1astol1c blood pressures averag1ng 115 mmHg. JAMA 202: 1028–1034Google Scholar
  201. 201.
    Veterans Adm1n1strat1on Cooperat1ve Study Group on Ant1hypertens1ve Agents (1970) Effects of treatment on morb1d1ty 1n hypertens1on. 2. Results 1n pat1ents w1th d1astol1c pressure averag1ng 90 through 114 mm Hg. JAMA 213: 1143–1152Google Scholar
  202. 202.
    V1bert1 GC, B1lous RW, MacK1ntosh D, Keen H (1983) Mon1tor1ng glomerular funct1on 1n d1abet1c nephropathy. A prospect1ve study. Am J Med 74: 256–264PubMedGoogle Scholar
  203. 203.
    V1bert1 GC, Jarrett RJ, Mahmud U, Holl RD, Argyropoulos A, Keen H (1982) M1croalbum1nur1a as a pred1ctor of cl1n1cal nephropathy 1n 1nsul1n-dependent d1abetes mell1tus. Lancet 1: 1430–1432PubMedGoogle Scholar
  204. 204.
    V1bert1 GC, Keen H, W1seman MJ (1987) Ra1sed arter1al pressure 1n parents of prote1n-ur1c 1nsul1n-dependent d1abetes. Br Med J 295: 515–517Google Scholar
  205. 205.
    V1dt DG, Bravo EL, Fouad FM (1982) Captopr1l. N Engl J Med 306: 214–219Google Scholar
  206. 206.
    Voors AW, Radhakr1shnamurty B, Sr1n1vasan SR, Webber LS, Berenson GS (1981) Plasma glucose level related to blood pressure 1n 272 ch1ldren, aged 7–15 years, sampled from a total b1rac1al populat1on. Am J Ep1dem1ol 113: 347–356Google Scholar
  207. 207.
    Waal-Mann1ng HJ (1979) Can beta-blockers be used 1n d1abet1c pat1ents? Drugs 17: 157–160PubMedGoogle Scholar
  208. 208.
    Waal-Mann1ng HJ, S1mpson FO (1977) Beta-blockers and l1p1d metabol1sm. Br Med J 2: 705PubMedGoogle Scholar
  209. 209.
    Wada S, Makayama M, Masak1 K (1982) Effects of d1lt1azem hydrochlor1de on serum l1p1ds: compar1son w1th beta-blockers. Cl1n Ther 5: 163–173Google Scholar
  210. 210.
    Warram Jh, Mart1n BC, Gleason RE, Soeldner JS (1987) Slow glucose removal rate but not 1nsul1n secret1on pred1cts development of N1DDM 1n offspr1ng of two N1DDM parents. D1abetes 36 [suppl. 1]: 14AGoogle Scholar
  211. 211.
    We1dmann P (1980) Recent pathogen1c aspects 1n essent1al hypertens1on and hypertens1on assoc1ated w1th d1abetes mell1tus. Kl1n Wochenschr 58: 1071–1089Google Scholar
  212. 212.
    We1dmann P, Beretta-P1ccol1 C, Keusch G, Gluck Z, Mujag1c M, Gr1mm M, Me1er A, Z1egler WH (1979) Sod1um-volume factor, card1ovascular react1v1ty and hypotens1ve mechan1sm of d1uret1c therapy 1n m1ld hypertens1on assoc1ated w1th d1abetes mell1tus. Am J Med 67: 779–784PubMedGoogle Scholar
  213. 213.
    We1dmann P, Beretta-P1ccol1 C, Trost BN (1985) Pressor factors and respons1veness 1n hypertens1on accompany1ng d1abetes mell1tus. Hypertens1on 7 [suppl. 2]: 33–42Google Scholar
  214. 214.
    We1nberger MH (1985) Ant1hypertens1ve Therapy and l1p1ds: ev1dence, mechan1sms and 1mpl1cat1ons. Arch 1ntern Med 145: 1102–1105Google Scholar
  215. 215.
    We1nberger MH, We1r RJ (1983) Oral contracept1ves and hypertens1on. 1n: Robertson J1S (ed) Handbook of hypertens1on, vol 2. Elsev1er, Amsterdam, pp 196–207Google Scholar
  216. 216.
    Welborn TA, Breckenr1dge A, D1llery CT, Rub1nste1n AH, Fraser TR (1966) Serum-1nsul1n 1n essent1al hypertens1on and 1n per1pheral vascular d1sease. Lancet 1: 1336–1337PubMedGoogle Scholar
  217. 217.
    Werle E, Korsten H (1938) Der Kall1kre1ngehalt des Harns, des Spe1chels and des Blutes be1 Gesunden and Kranken. Z Ges Exp Med 103: 153–156Google Scholar
  218. 218.
    Westermark P (1972) Quant1tat1ve stud1es of amylo1d 1n the 1slets of Langerhans. Uppsala J Med Sc1 77: 91–94Google Scholar
  219. 219.
    Westermark P, Wernstedt C, O’Br1en TD, Hayden DW, Johnson KH (1987) 1slet amylo1d 1n type 2 human d1abetes mell1tus and adult d1abet1c cats conta1ns a novel putat1ve polypept1de hormone. Am J Pathol 127: 414–417Google Scholar
  220. 220.
    Wh1tcroft EA, Thomas JM, Rawsthorne A, W1lk1nson N, Thompson H (1990) Effects of alpha and beta adrenoceptor block1ng drugs and ACE 1nh1b1tors on long-term glucose and l1p1d control 1n hypertens1ve non-1nsul1n dependent d1abet1cs. Horm Metab Res [suppl. 22]: 42–46Google Scholar
  221. 221.
    W1cklmayr M, D1etze G (1977) Effect of oral kall1kre1n and 1ntrabrach1al-arter1al bradyk1n1n on forearm metabol1sm 1n matur1ty onset d1abet1cs. 1n: Haberland GL, Rohen JW, Suzuk1 T (eds) K1n1nogenases. Schattauer, Stuttgart New York, pp 299–321Google Scholar
  222. 222.
    W1lhelmsen L, Berglund G, Elmfeldt D, F1tzs1mons T, Holzgreve H, Hos1e J, Hörnkv1st PE, Pennert K, Tuom1lehto J, Wedel H (1987) Beta-blockers versus d1uret1cs 1n hypertens1ve men: ma1n results from the HAPPY tr1al. J Hypertens 5: 561–572PubMedGoogle Scholar
  223. 223.
    W1ngard DL, Barrett-Connor E (1987) Fam1ly h1story of d1abetes and card1ovascular d1sease r1sk factors and mortal1ty among euglycem1c borderl1ne hyperglycem1c and d1abet1c adults. Am J Ep1dem1ol 125: 948–958Google Scholar
  224. 224.
    W1nocour PH, Waldek S, Johns CW, Ohar H, Anderson DC (1986) Captopr1l may adversely affect renal funct1on 1n hypertens1ve d1abet1c w1thout establ1shed nephropathy. J Endocr1nol 108 [suppl.]: 216Google Scholar
  225. 225.
    W1seman MJ, V1bert1 GC, Mack1ntosh D, Jarrett RJ, Keen H (1984) Glycem1a, arter1al pressure and m1croalbum1nur1a 1n type 1 (1nsul1n-dependent) d1abetes mell1tus. D1abetolog1a 26: 401–405Google Scholar
  226. 226.
    Work1ng Group of Hypertens1on (1987) Statement on hypertens1on. D1abetes Care 10: 764–776Google Scholar
  227. 227.
    Wr1ght AD, Penny ME (1980) Beta-blockers and hypoglycem1a. D1abetes Care 3: 204–205Google Scholar
  228. 228.
    Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM (1986) Prevent1on of d1abet1c glomerulopathy by pharmacolog1cal amel1orat1on of glomerular cap1llary hypertens1on. J Cl1n 1nvest 77: 1925–1930Google Scholar
  229. 229.
    Zatz R, Meyer TM, Rennke HG, Brenner BM (1985) Predom1nance of hemodynam1c rather than metabol1c factors 1n the pathogenes1s of d1abet1c glomerulopathy. Proc Natl Acad Sc1 USA 82: 5963–5967Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • R. G. Bretzel

There are no affiliations available

Personalised recommendations